Platelet Transfusion Therapy

Hematology/Oncology Clinics of North America

Volumn 21, Issue 4, 2007, Pages 697-729

  Slichter, Sherrill J ^a,b  

^a PUGET SOUND BLOOD CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; THROMBOCYTE CONCENTRATE; THROMBOPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALLOIMMUNIZATION; APHERESIS; BACTERIAL TRANSMISSION; BACTERIUM CONTAMINATION; BLEEDING; BLEEDING TIME; BLOOD COMPATIBILITY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL ASSESSMENT; DISEASE CLASSIFICATION; GAMMA IRRADIATION; GRAFT VERSUS HOST REACTION; HEMOSTASIS; HUMAN; LEUKAPHERESIS; LYMPHOCYTOTOXICITY; MICROBIOLOGICAL EXAMINATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; THROMBOCYTE PRESERVATION; THROMBOCYTE RICH PLASMA; THROMBOCYTE TRANSFUSION; THROMBOCYTE VOLUME; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; TREATMENT RESPONSE; VIRUS TRANSMISSION;

BLOOD GROUPING AND CROSSMATCHING; BLOOD PLATELETS; CELL SURVIVAL; HUMANS; PLATELET COUNT; PLATELET TRANSFUSION; TREATMENT OUTCOME;

EID: 34547135441     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.06.010     Document Type: Review

References (128)

1. Sullivan M.T., and Wallace E.L. Blood collection and transfusion in the United States in 1999. Transfusion 45 (2005) 141-148
2. Balducci L., Benson K., Lyman G.H., et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. Transfusion 33 (1993) 665-670
3. Bernstein S.H., Nademanee A.P., Vose J.M., et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 91 (1998) 3509-3517
4. Meehan K.R., Matias C.O., Rathore S.S., et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 64 (2000) 251-256
5. Slichter S.J., and Harker L.A. Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood. Br J Haematol 34 (1976) 395-402
6. Pietersz R.N.I., Loos J.A., and Reesink H.W. Platelet concentrates stored in plasma for 72 hours at 22°C prepared from buffy coats of citrate-phosphate-dextrose blood collected in a quadruple-bag saline-adenine-glucose-mannitol system. Vox Sang 49 (1985) 81-85
7. 51Cr. Transfusion 32 (1992) 113-120
8. Anderson N.A., Gray S., Copplestone J.A., et al. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfus Med 7 (1997) 33-39
9. van Delden C.J., de Wit H.J.C., and Smit Sibinga C.T. Comparison of blood component preparation systems based on buffy coat removal: component specifications, efficiency, and process costs. Transfusion 38 (1998) 860-866
10. Bertolini F., Rebulla P., Riccardi D., et al. Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Transfusion 29 (1989) 605-609
11. Slichter S.J., Jones M.K., Christoffel T., et al. Long-term platelet storage: In vivo platelet viability maintained for 8 days in plasma and 13 days in Plasmalyte. [abstract]. Blood 102 11, Part 1 (2003) 93a
12. Slichter S.J., Bolgiano D., Corson J., et al. In vivo evaluation of extended stored platelet concentrates. [abstract]. Blood 108 11, Part 1 (2006) 282a-283a
13. Schreiber G.B., Busch M.P., Kleinman S.H., et al. The risk of transfusion-transmitted viral infections. The retrovirus epidemiology donor study. N Engl J Med 334 (1996) 1685-1690
14. Ness P., Braine H., King K., et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 41 (2001) 857-861
15. In: Fridey J.L. (Ed). Standards for blood banks and transfusion services. 2nd edition (2003), American Association of Blood Banks, Bethesda (MD) 13
16. The Trial To Reduce Alloimmunization To Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 337 (1997) 1861-1869
17. Lopez-Plaza I., Weissfeld J., and Triulzi D.J. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 39 (1999) 925-932
18. Cable R.G., and Edwards R.L. The use of platelet concentrates versus plateletpheresis-the donor perspective. [editorial]. Transfusion 41 (2001) 727-729
19. Cardigan R., and Williamson L.M. The quality of platelets after storage for 7 days. Transfus Med 13 (2003) 173-187
20. Chambers L.A., and Herman J.H. Considerations in the selection of a platelet component: apheresis versus whole blood-derived. Transfus Med Rev 13 (1999) 311-322
21. Bowden R.A., Slichter S.J., Sayers M., et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplantation. Blood 86 (1995) 3598-3603
22. Heddle N.M., Blajchman M.A., Meyer R.M., et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 42 (2002) 556-566
23. Dzik S., AuBuchon J., Jeffries L., et al. Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 14 (2000) 34-52
24. Vamvakas E.C., and Blajchman M.A. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?. Blood 97 (2001) 1180-1195
25. Vamvakas E.C., and Blajchman M.A. Universal WBC reduction: the case for and against. Transfusion 41 (2001) 691-712
26. Kao K.J., Mickel M., Braine H.G., et al. White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial. Transfusion 35 (1995) 13-19
27. Leitman S.F. Use of blood cell irradiation in the prevention of posttransfusion graft-versus-host disease. Transfus Sci 10 (1989) 219-232
28. Moroff G., George V.M., Siegl A.M., et al. The influence of irradiation on stored platelets. Transfusion 26 (1986) 453-456
29. Slichter S.J., Davis K., Enright H., et al. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 105 (2005) 4106-4114
30. Saxonhouse M., Slayton W., and Sola M.C. Platelet transfusions in the infant and child. In: Hillyer C.D., Luban N.L.C., and Strauss R.G. (Eds). Handbook of pediatric transfusion medicine (2004), Elisevier Academic Press, San Diego (CA) 253-269
31. Schoenfeld H., Muhm M., Doepfmer U.R., et al. The functional integrity of platelets in volume-reduced platelet concentrates. Anesth Analg 100 (2005) 78-81
32. Dumont L.J., AuBuchon J.P., Whitley P., et al. Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 42 (2002) 847-854
33. Slichter S.J., Bolgiano D., Jones M.K., et al. Viability and function of 8-day stored apheresis platelets. Transfusion 46 (2006) 1763-1769
34. Hanson S.R., and Slichter S.J. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 56 (1985) 1105-1109
35. Holme S., and Heaton A. In vitro platelet aging at 22°C is reduced compared to in vivo aging at 37°C. Br J Haematol 91 (1995) 212-218
36. Wagner S.J., Moroff G., Katz A.J., et al. Comparison of bacteria growth in single and pooled platelet concentrates after deliberate inoculation and storage. Transfusion 35 (1995) 298-302
37. Harker L.A. The role of the spleen in thrombokinetics. J Lab Clin Med 77 (1971) 247-253
38. O'Connell B., Lee E.J., and Schiffer C.A. The value of 10-minute posttransfusion platelet counts. Transfusion 28 (1988) 66-67
39. Davis K.B., Slichter S.J., and Corash L. Corrected count increment and percent platelet recovery as measures of post-transfusion platelet response: problems and a solution. Transfusion 39 (1999) 586-592
40. Schlossberg H.R., and Herman J.H. Platelet dosing. Transfus Apher Sci 28 (2003) 221-226
41. Vostal J.G. Efficacy evaluation of current and future platelet transfusion products. J Trauma 6 Suppl (2006) S78-S82
42. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
43. Harker L.A., and Slichter S.J. The bleeding time as a screening test for evaluating platelet function. N Engl J Med 287 (1972) 155-159
44. Blajchman M.A., Senyl A.P., Hirsh J., et al. Hemostatic function, survival, and membrane glycoprotein changes in young versus old rabbit platelets. J Clin Invest 68 (1981) 1289-1294
45. Slichter S.J., and Harker L.A. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 7 (1978) 523-539
46. Blajchman M.A., Beckers E.A.M., Dickmeiss E., et al. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 19 (2005) 259-272
47. McDonald C.P., Low P., Roy A., et al. Evaluation of donor arm disinfection techniques. Vox Sang 80 (2001) 135-141
48. de Korte D., Marcelis J.H., Verhoeven A.J., et al. Diversion of the first blood volume results in a reduction of bacterial contamination for whole-blood collections. Vox Sang 83 (2002) 13-16
49. Brecher M.E., Means N., Jere C.S., et al. Evaluation of an automated culture system for detecting bacterial contamination of platelets: an analysis with 15 contaminating organisms. Transfusion 41 (2001) 477-482
50. Ortolano G.A., Freundlich L.F., Holme S., et al. Detection of bacteria in WBC-reduced PLT concentrates using percent oxygen as a marker for bacteria growth. Transfusion 43 (2003) 1276-1284
51. Heddle N.M., Cook R.J., Blajchman M.A., et al. Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial. Transfusion 45 (2005) 896-903
52. Lin L., Cook D.N., Wiesehahn G.P., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37 (1997) 423-435
53. Goodrich R.P. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 78 Suppl 2 (2000) 211-215
54. 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 44 (2004) 1732-1740
55. AuBuchon J.P., Herschel L., Roger J., et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 45 (2005) 1335-1341
56. McCullough J., Vesole D.H., Benjamin R.J., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 104 5 (2004) 1534-1541
57. Slichter S.J., Raife T.J., Davis K., et al. Platelets photochemically-treated with amotosalen HCL and ultraviolet A light correct prolonged bleeding times in thrombocytopenic patients. Transfusion 46 5 (2006) 731-740
58. Heddle N.M. Febrile nonhemolytic transfusion reactions to platelets. Curr Opin Hematol 2 (1995) 478-483
59. Boehlen F., and Clemetson K.J. Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice?. Transfus Med 11 (2001) 403-417
60. Aster R.H. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 26 (1965) 732-743
61. Carr R., Hutton J.L., Jenkins J.A., et al. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 75 (1990) 408-413
62. Semple J.W., and Freed J. The basic immunology of platelet-induced alloimmunization. In: Kickler T.S., and Herman J.H. (Eds). Current issues in platelet transfusion therapy and platelet alloimmunity (1999), American Association of Blood Banks, Bethesda (MD) 77-101
63. Class F.H., Smeenk R.J., Schmidt R., et al. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 9 (1981) 84-89
64. Kripke M.L. Immunologic unresponsiveness induced by ultraviolet radiation. Immunol Rev 80 (1984) 87-102
65. Schiffer C.A., Dutcher J.P., Aisner J., et al. A randomized trial of leukocyte-depleted platelet transfusions to modify alloimmunization in patients with leukemia. Blood 62 (1983) 815-820
66. Murphy M.F., Metcalfe P., Thomas H., et al. Use of leucocyte-poor blood components in HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 62 (1986) 529-534
67. Sniecinski I., O'Donnell M.R., Nowicki B., et al. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 71 (1988) 1402-1407
68. Andreu G., Dewailly J., Leberre C., et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 72 (1988) 964-969
69. Oksanen K., Kekomaki R., Ruutu T., et al. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components-a randomized trial. Transfusion 31 (1991) 588-594
70. van Marwijk Kooy M., van Prooijen H.C., Moes M., et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 77 (1991) 201-205
71. Williamson L.M., Wimperis J.Z., Williamson P., et al. Bedside filtration of blood products in the prevention of HLA alloimmunization-a prospective randomized study. Blood 83 (1994) 3028-3035
72. Brand A., van de Watering L.M.G., and Claas F.H.J. Clinical significance of leukoreduction of blood components. Vox Sang 78 Suppl 2 (2000) 227-229
73. Slichter S.J. Platelet alloimmunization. In: Anderson K.C., and Ness P. (Eds). Scientific basis of transfusion medicine (1994), WB Saunders Company, Orlando (FL) 527-543
74. Slichter S.J. Understanding the effects of different types of white cells on patient's responses to transfusion: immunization versus tolerizaton. Vox Sang 83 Suppl 1 (2002) 421-424
75. Semple J.W., Speck E.R., Crosgrave D., et al. Extreme leukoreduction of major histocompatibility complex Class II positive B cells enhances allogeneic platelet immunity. Blood 93 (1999) 713-720
76. Sowemimo-Coker S.O., Kim A., Tribble E., et al. White cell subsets in apheresis and filtered platelet concentrates. Transfusion 38 (1998) 650-657
77. Freeman J., Blanchette V., Hornstein A., et al. White cell depletion of red cell and pooled random-donor platelet concentrates by filtration and residual lymphocyte subset analysis. Transfusion 31 (1991) 433-440
78. Roy A.J., Jaffe N., and Djerassi I. Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion 13 (1973) 283-290
79. Higby D.J., Cohen E., Holland J.F., et al. The prophylactic treatment of thrombocytopenic leukemia patients with platelets: a double blind study. Transfusion 14 (1974) 440-446
80. Slichter S.J. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfusion Medicine Reviews 18 (2004) 153-167
81. Wandt H., Schaefer-Eckart K., Frank M., et al. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37 (2006) 387-392
82. Gaydos L.A., Freireich E.J., and Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266 (1962) 905-909
83. Zumberg M.S., del Rosario M.L., Nejame C.F., et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/μL versus 20,000/μL trigger. Biol Blood Marrow Transplant 8 (2002) 569-576
84. Rebulla P., Finazzi G., Marangoni F., et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 337 (1997) 1870-1875
85. 9/l: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91 (1998) 3601-3606
86. Heckman K.D., Weiner G.J., Davis C.S., et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL. J Clin Oncol 15 (1997) 1143-1149
87. Segal H.C., Briggs C., Kunka S., et al. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. Br J Haematol 128 (2005) 520-525
88. Norris S., Pantelidou D., Smith D., et al. Immunoplatelet counting: potential for reducing the use of platelet transfusions through more accurate platelet counting. Br J Haematol 121 (2003) 605-613
89. Chaoui D., Chakroun T., Robert F., et al. Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy. Transfusion 45 (2005) 766-772
90. Slichter S.J., LeBlanc R., Jones M.K., et al. Quantitative analysis of bleeding risk in cancer patients prophylactically transfused at platelet counts of 5,000, 10,000, or 20,000 plts/μl. [abstract]. Blood 94 Suppl 1 (1999) 376a
91. Schiffer C.A., Anderson K.C., Bennett C.L., et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1519-1538
92. British Committee for Standards in Haematology, and Blood Transfusion Task Force (Chairman P Kelsey). Guidelines for the use of platelet transfusions. Br J Haematol 122 (2003) 10-23
93. Tinmouth A.T., and Freedman J. Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfus Med Rev 17 (2003) 181-193
94. Goodnough L.T., Kuter D.J., McCullough J., et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 98 (2001) 1346-1351
95. Norol F., Bierling P., Roudot-Thoraval F., et al. Platelet transfusion: a dose-response study. Blood 92 (1998) 1448-1453
96. Klumpp T.R., Herman J.H., Gaughan J.P., et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. Transfusion 39 (1999) 674-681
97. Hersh J.K., Hom E.G., and Brecher M.E. Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion-dependent patient. Transfusion 38 (1998) 637-644
98. Ackerman S.J., Klumpp T.R., Guzman G.I., et al. Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion 40 (2000) 1457-1462
99. Slichter S.J. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apheresis 21 (2006) 78-84
100. Kuter D.J. Whatever happened to thrombopoietin. [editorial]. Transfusion 42 (2002) 279-283
101. Folman C.C., de Jong S.M., de Haas M., et al. Analysis of the kinetics of TPO uptake during platelet transfusion. Transfusion 41 (2001) 517-521
102. Lawrence J.B., Yomtovian R.A., Dillman C., et al. Reliability of automated platelet counts: comparison with manual method and utility for prediction of clinical bleeding. Am J Hematol 48 (1995) 244-250
103. Heddle N.M., Cook R.J., Sigouin C., et al. A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion 46 (2006) 903-911
104. Slichter S.J., Murphy S., Buchholz D., et al. INTERCEPT platelets and conventional platelets provide comparable hemostatic responses in thrombocytopenic patients: the SPRINT trial. [abstract]. Blood 100 11, Part 2 (2002) 141b
105. Webert K.E., Cook R.J., Sigouin C.S., et al. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 91 (2006) 1530-1537
106. Friedman A.M., Sengul H., Lehmann H., et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A re-evaluation of prophylactic platelet transfusions. Transfus Med Rev 16 (2002) 34-45
107. Kim H., Lee J.H., Choi S.J., et al. Risk score model for fatal intracranial hemorrhage in acute leukemia. Leukemia 20 (2006) 770-776
108. Slichter S.J., and Harker L.A. Hemostasis in malignancy. Ann N Y Acad Sci 230 (1974) 252-261
109. Arbuthnot C., and Wilde J.T. Haemostatic problems in acute promyelocytic leukaemia. Blood Rev 20 (2006) 289-297
110. Tallman M.S., Brenner B., and de la Serna J. Meeting report. Leuk Res 29 (2005) 347-351
111. Rickles F.R. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16 (2003) 463-482
112. Tornebohm E., Lockner D., and Paul C. A retrospective analysis of bleeding complications in 438 patients with acute leukemia during the years 1972-1991. Eur J Haematol 50 (1993) 160-167
113. Nevo S., Swan V., Enger C., et al. Acute bleeding after bone marrow transplantation: incidence and effect on survival. A quantitative analysis in 1,402 patients. Blood 91 (1998) 1469-1477
114. Belt R.J., Leite C., Haas C.D., et al. Incidence of hemorrhagic complications in patients with cancer. JAMA 239 (1978) 2571-2574
115. Dutcher J.P., Schiffer C.A., Aisner J., et al. Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. Cancer 53 (1984) 557-562
116. Goldberg G.L., Gibbon D.G., Smith H.O., et al. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. J Clin Oncol 12 (1994) 2317-2320
117. Fanning J., Hilgers R.D., Murray K.P., et al. Conservative management of chemotherapeutic-induced thrombocytopenia in women with gynecologic cancers. Gynecol Oncol 59 (1995) 191-193
118. Elting L.S., Rubenstein E.B., Martin C.G., et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19 (2001) 1137-1146
119. Sacher R.A., Kickler T., Schiffer C.A., et al. Management of patients refractory to platelet transfusion. Arch Pathol Lab Med 127 (2003) 409-414
120. Delaflor-Weiss E., and Mintz P.D. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 14 (2000) 180-196
121. Slichter S.J. Algorithm for managing the platelet refractory patient. J Clin Apher 23 (1997) 4-9
122. Duquesnoy R.J. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 63 (2002) 339-352
123. Namblar A., Duquesnoy R.J., Adams S., et al. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 107 (2006) 1680-1687
124. Ishida A., Handa M., Wakui M., et al. Clinical factors influencing posttransfusion platelet increments in patients undergoing hematopoietic progenitor cell transplantation: a prospective analysis. Transfusion 38 (1998) 839-847
125. McFarland J. Alloimmunization and platelet transfusion. Semin Hematol 33 (1996) 315-328
126. Kalmadi S., Tiu R., Lowe C., et al. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 107 (2006) 136-140
127. Culligan D.J., Salamat A., Tait J., et al. Use of recombinant factor VIIa in life-threatening bleeding following autologous peripheral blood stem cell transplantation complicated by platelet refractoriness. [correspondence]. Bone Marrow Transplant 31 (2003) 1183-1184
128. Vidarsson B., and Ondundarson P.T. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 83 (2000) 634-635